Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
More News related to BMRN
- Roth Capital Upgrades BioMarin Pharmaceutical (BMRN) to Buy
- Notable Analyst Rating Changes of the Day 02/08: HD, AMZN, ARAY, WGO Upgraded; BMRN, ARG, HK Downgraded
- Brean Murray Downgrades BioMarin Pharmaceutical (BMRN) to Hold; Valuation Call
- BioMarin Announces 2010 Guidance
- BioMarin to Acquire LEAD Therapeutics
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Credit Suisse upgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Neutral to Overweight. Price target increased from $19 to $25.
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
